Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease.

Literature DB >> 33573211

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease.

Caitlin V M L Jie¹, Valerie Treyer², Roger Schibli¹, Linjing Mu^1,2.

Abstract

Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.

Entities: Chemical Disease Gene Species

Keywords: PET; [18F]flortaucipir; alzheimer’s disease; tau neurofibrillary tangles (NFTs); tauvid™

Year: 2021 PMID： 33573211 PMCID： PMC7911942 DOI： 10.3390/ph14020110

Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN： 1424-8247

55 in total

1. Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.

Authors: Eric D Hostetler; Abbas M Walji; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Hyking Haley; Marie Holahan; Mona Purcell; Kerry Riffel; Talakad G Lohith; Paul Coleman; Aileen Soriano; Aimie Ogawa; Serena Xu; Xiaoping Zhang; Elizabeth Joshi; Joseph Della Rocca; David Hesk; David J Schenk; Jeffrey L Evelhoch
Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057

2. Frequency of stages of Alzheimer-related lesions in different age categories.

Authors: H Braak; E Braak
Journal: Neurobiol Aging Date: 1997 Jul-Aug Impact factor: 4.673

3. Pharmacokinetic Evaluation of the Tau PET Radiotracer ¹⁸F-T807 (¹⁸F-AV-1451) in Human Subjects.

Authors: Dustin W Wooten; Nicolas J Guehl; Eline E Verwer; Timothy M Shoup; Daniel L Yokell; Nevena Zubcevik; Neil Vasdev; Ross D Zafonte; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal: J Nucl Med Date: 2016-09-22 Impact factor: 10.057

4. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.

Authors: Adam S Fleisher; Michael J Pontecorvo; Michael D Devous; Ming Lu; Anupa K Arora; Stephen P Truocchio; Patricia Aldea; Matthew Flitter; Tricia Locascio; Marybeth Devine; Andrew Siderowf; Thomas G Beach; Thomas J Montine; Geidy E Serrano; Craig Curtis; Allison Perrin; Stephen Salloway; Misty Daniel; Charles Wellman; Abhinay D Joshi; David J Irwin; Val J Lowe; William W Seeley; Milos D Ikonomovic; Joseph C Masdeu; Ian Kennedy; Thomas Harris; Michael Navitsky; Sudeepti Southekal; Mark A Mintun
Journal: JAMA Neurol Date: 2020-07-01 Impact factor: 18.302

5. Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.

Authors: Renaud La Joie; Adrienne V Visani; Suzanne L Baker; Jesse A Brown; Viktoriya Bourakova; Jungho Cha; Kiran Chaudhary; Lauren Edwards; Leonardo Iaccarino; Mustafa Janabi; Orit H Lesman-Segev; Zachary A Miller; David C Perry; James P O'Neil; Julie Pham; Julio C Rojas; Howard J Rosen; William W Seeley; Richard M Tsai; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal: Sci Transl Med Date: 2020-01-01 Impact factor: 17.956

Review 6. Fluorine-18 radiochemistry, labeling strategies and synthetic routes.

Authors: Orit Jacobson; Dale O Kiesewetter; Xiaoyuan Chen
Journal: Bioconjug Chem Date: 2014-12-12 Impact factor: 4.774

7. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Authors: Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances
Journal: Sci Transl Med Date: 2016-05-11 Impact factor: 17.956

8. Tau and atrophy: domain-specific relationships with cognition.

Authors: Leonardino A Digma; John R Madsen; Emilie T Reas; Anders M Dale; James B Brewer; Sarah J Banks
Journal: Alzheimers Res Ther Date: 2019-07-27 Impact factor: 6.982

9. Tau PET imaging with ¹⁸F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study.

Authors: Andre Mueller; Santiago Bullich; Olivier Barret; Jennifer Madonia; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens
Journal: J Nucl Med Date: 2019-11-11 Impact factor: 11.082

10. ¹⁸F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

Authors: Ruben Smith; Michael Schöll; Elisabet Londos; Tomas Ohlsson; Oskar Hansson
Journal: Sci Rep Date: 2018-03-16 Impact factor: 4.379

7 in total

Review 1. The role of neuroimaging in Parkinson's disease.

Authors: Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal: J Neurochem Date: 2021-10-03 Impact factor: 5.546

Review 2. Alzheimer's disease clinical trial update 2019-2021.

Authors: Joseph Pleen; Ryan Townley
Journal: J Neurol Date: 2021-10-05 Impact factor: 6.682

Review 3. Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective.

Authors: Maria Ricci; Andrea Cimini; Riccardo Camedda; Agostino Chiaravalloti; Orazio Schillaci
Journal: Int J Mol Sci Date: 2021-11-30 Impact factor: 5.923

4. Epitope alteration by small molecules and applications in drug discovery.

Authors: Biyue Zhu; Jing Yang; Richard Van; Fan Yang; Yue Yu; Astra Yu; Kathleen Ran; Keyi Yin; Yingxia Liang; Xunuo Shen; Wei Yin; Se Hoon Choi; Ying Lu; Changning Wang; Yihan Shao; Liang Shi; Rudolph E Tanzi; Can Zhang; Yan Cheng; Zhirong Zhang; Chongzhao Ran
Journal: Chem Sci Date: 2022-06-28 Impact factor: 9.969

5. Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease.

Authors: Natasha Krishnadas; Kun Huang; Stephanie A Schultz; Vincent Doré; Pierrick Bourgeat; Anita M Y Goh; Fiona Lamb; Svetlana Bozinovski; Samantha C Burnham; Joanne S Robertson; Simon M Laws; Paul Maruff; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160

6. Brain PET motion correction using 3D face-shape model: the first clinical study.

Authors: Yuma Iwao; Go Akamatsu; Hideaki Tashima; Miwako Takahashi; Taiga Yamaya
Journal: Ann Nucl Med Date: 2022-07-19 Impact factor: 2.258

Review 7. Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody-mediated encephalitis and coronavirus disease 2019.

Authors: Dror Shir; Gregory S Day
Journal: Curr Opin Neurol Date: 2022-04-01 Impact factor: 5.710

7 in total